Shilajit Benefits: What the Evidence Actually Supports

This is the area with the strongest human clinical evidence. A randomised, double-blind, placebo-controlled trial published in Andrologia (2016) enrolled 96 infertile men and found significant improvements in total sperm count, motility, and testosterone after 90 days of shilajit supplementation (200 mg twice daily). Biswas TK et al., Andrologia 2010.

A separate RCT by Pandit et al. (2016) in healthy male volunteers aged 45–55 found that purified shilajit (250 mg twice daily for 90 days) significantly increased total testosterone, free testosterone, and DHEAS compared with placebo, with no adverse effects reported. Pandit S et al., Andrologia 2016.

The mechanism is not fully established but may involve stimulation of luteinising hormone (LH) and follicle-stimulating hormone (FSH) at the pituitary level, as well as gonadotropin activity in testicular Leydig cells.

A double-blind, placebo-controlled study in subjects with chronic fatigue syndrome found that shilajit (200 mg twice daily, 12 weeks) significantly reduced subjective fatigue scores and improved markers of mitochondrial function compared with placebo. Surapaneni DK et al., J Ethnopharmacol 2012.

A separate study examined shilajit's effect on skeletal muscle. Subjects taking 500 mg/day for 8 weeks showed less post-exercise decline in maximum strength (measured by bench press) compared to placebo, suggesting a role in muscle recovery. Keller JL et al., J Int Soc Sports Nutr 2019.

The proposed mechanism involves shilajit's effect on mitochondrial CoQ10 and its role in the electron transport chain — essentially making mitochondria more efficient at producing ATP.

The cognitive research on shilajit is mechanistically compelling but human trial data is limited. In laboratory models, fulvic acid has been shown to inhibit tau protein aggregation — a key pathological feature of Alzheimer's disease — and disaggregate pre-formed tau filaments in vitro. Carrasco-Gallardo C et al., Int J Alzheimers Dis 2012.

In animal models, shilajit has shown benefits in spatial memory tasks and reduced amyloid-β plaque formation. No large-scale human RCTs on cognitive outcomes have been published. This remains a promising but unproven area.

A study in women with iron deficiency anaemia found that shilajit supplementation improved haemoglobin levels, red blood cell count, and haematocrit values over 12 weeks. Trivedi NA et al., J Ethnopharmacol 2011.

Fulvic acid's chelating properties are believed to enhance non-haem iron bioavailability by maintaining iron in its ferrous (Fe²⁺) form, which is more readily absorbed than ferric (Fe³⁺) iron. This makes shilajit of particular interest for women, vegetarians, and athletes with high iron turnover.

Some users report improved sleep quality with shilajit supplementation. The biological rationale involves shilajit's effect on GABA receptor activity — an inhibitory neurotransmitter pathway involved in sleep onset — and its adaptogenic properties, which may reduce cortisol-mediated arousal. However, controlled human trials specifically examining sleep outcomes are not yet available. The evidence here is largely anecdotal and mechanistic rather than empirical.

Traditional use of shilajit at altitude dates back thousands of years in Himalayan and Tibetan medicine. A review published in the International Journal of Ayurveda Research documented its traditional use for reducing symptoms of altitude sickness, attributing the effect to its ability to promote erythropoiesis (red blood cell production) and improve oxygen delivery at the cellular level. Meena H et al., Int J Ayurveda Res 2010. Controlled human trials at altitude are limited.

Multiple in-vitro studies demonstrate that fulvic acid and shilajit fractions inhibit pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Free radical scavenging activity has been documented in several laboratory studies. Schepetkin IA et al., J Agric Food Chem 2009. Human trials measuring inflammatory markers as primary outcomes are lacking.